Company News »

Compugen Appoints Mr. Ari Krashin as Chief Financial Officer

Business Wire
Share on StockTwits
Published on

Compugen Ltd. (NASDAQ: CGEN),
a leading drug discovery company focused on therapeutic proteins and
monoclonal antibodies in the fields of immunology and oncology, today
announced the appointment of Mr. Ari Krashin as Chief Financial Officer,
effective as of September 9, 2014. Mr. Krashin will report to Dr. Anat
Cohen Dayag, Compugen’s President and Chief Executive Officer, and will
have direct responsibility for all financial functions of the company,
including investor relations, and in addition will oversee the legal

Dr. Cohen-Dayag stated, “With over 15 years of experience in all aspects
of finance, investor relations, M&A and business development, Mr.
Krashin brings substantial global finance expertise to Compugen. We very
much look forward to Mr. Krashin’s contribution to our senior management
team, particularly during this period of anticipated rapid growth and
expansion for our company.”

Mr. Krashin added, “I am enthusiastic about joining Compugen and its
dedicated management team at this pivotal time in the Company’s
development, and hope my experience will contribute to its future

Mr. Krashin previously served as Chief Financial Officer of Gilat
Satellite Networks (Nasdaq: GILT) where he was responsible for the
company’s global finance and related operations, including M&A, business
development, investor relations and administration. Prior to his
position as CFO of Gilat, Mr. Krashin held a variety of senior financial
positions in Gilat. Mr. Krashin also served as CFO of Spacenet, a US
subsidiary of Gilat. In addition, he recently served as CFO of AnyClip
Media. Mr. Krashin is a certified public accountant and began his
professional career with Kesselman and Kesselman, PWC, Israel.

About Compugen

Compugen is a leading drug discovery company focused on therapeutic
proteins and monoclonal antibodies to address important unmet needs in
the fields of immunology and oncology. The Company utilizes a broad and
continuously growing integrated infrastructure of proprietary scientific
understandings and predictive platforms, algorithms, machine learning
systems and other computational biology capabilities for the in
(by computer) prediction and selection of product candidates,
which are then advanced in its Pipeline Program. The Company’s business
model includes collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery agreements,
in both cases providing Compugen with potential milestone payments and
royalties on product sales or other forms of revenue sharing. Compugen’s
wholly-owned U.S. subsidiary located in South San Francisco is
developing monoclonal antibody therapeutic candidates against its drug
targets. For additional information, please visit Compugen’s corporate
website at

This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements include words such as “may,” “expects,” “anticipates,”
“potential,” “believes,” and “intends,” and describe opinions about
future events. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different from
any future results, performance or achievements expressed or implied by
such forward-looking statements. Some of these risks and other factors
are discussed in the “Risk Factors” section of Compugen’s Annual Report
on Form 20-F for the year ended December 31, 2013 as filed with the
Securities and Exchange Commission. In addition, any forward-looking
statements represent Compugen’s views only as of the date of this
release and should not be relied upon as representing its views as of
any subsequent date. Compugen does not assume any obligation to update
any forward-looking statements unless required by law.

Share on StockTwits